查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
血脂异常治疗市场 - 预测 2023-2028
市场调查报告书
商品编码
1295410

血脂异常治疗市场 - 预测 2023-2028

Lipid Disorder Treatment Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 122 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年血脂异常治疗市场价值为262.69亿美元。

脂质（脂蛋白）是在血液中循环的脂肪。血脂异常是一种影响血脂水平的广泛代谢性疾病。血脂异常通常以血液中胆固醇、甘油三酯和脂蛋白水平升高为特征，并且与心血管疾病风险增加（或持续）相关。有几种简单的方法可以降低低密度脂蛋白，包括避免食用富含饱和脂肪、膳食胆固醇和过量热量的食物、锻炼、保持健康体重和戒烟。他汀类药物是治疗脂质最常用的处方治疗药物。

由于消费者不健康生活习惯的增加，各种与生活方式相关的疾病在世界范围内不断增加。高胆固醇水平患病率的增加和血脂异常治疗市场的不断发展可能会进一步促进市场增长。世界卫生组织 (WHO) 将三分之一的缺血性心脏病归因于高胆固醇水平。此外，吸烟和饮酒也导致血脂异常患病率上升，进一步推动市场增长。

该研究根据药物类型、分销渠道和地区等各个细分市场研究了血脂异常治疗市场的市场细分。首先，简要的市场概述详细介绍了主要驱动因素和挑战。接下来，我们利用波特五力模型对血脂异常治疗行业进行全面分析。然后进行价值链分析，以确定哪些公司属于不同的流程并对不同的领域做出贡献。

它还提供了有关市场发展、趋势、行业政策和影响血脂异常治疗市场的政策的详细信息。此外，该研究还分析了血脂异常治疗领域的整体监管框架，以增强利益相关者对影响整体市场格局的关键因素的理解。

《血脂异常治疗市场——2023年至2028年预测》是一份综合性的新报告。该报告向高管和感兴趣的利益相关者提供重要的市场信息，并提供重要的市场情报。它还分析了竞争格局，详细介绍了主要市场参与者的战略，并将其绘製在四象限供应商矩阵中：领导者、追随者、挑战者和利基市场。

血脂异常治疗市场研究报告的研究范围和目标如下：

  • 血脂异常治疗市场数据表和图表
  • 市场驱动因素、市场约束、波特分析、行业价值链分析
  • 按药物类型进行市场评估：洛伐他汀、阿托伐他汀、瑞舒伐他汀、其他
  • 按分销渠道详细的市场趋势、分析和图形显示：线上、线下
  • 血脂异常治疗市场的 360 度市场视图：按地区（北美、南美、欧洲、中东和非洲、亚太地区），该地区主要国家的详细市场细分

血脂异常治疗市场报告涵盖的各个细分市场是：

按药物类型

  • 洛伐他汀
  • 阿托伐他汀
  • 瑞舒伐他汀
  • 其他

按分销渠道

  • 在线的
  • 离线

按地区

  • 北美
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 欧洲
  • 英国
  • 德国
  • 法国
  • 西班牙
  • 其他中东/非洲
  • 沙特阿拉伯
  • 阿拉伯联合酋长国
  • 以色列
  • 其他
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 印度尼西亚
  • 泰国

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场细分
  • 货币
  • 先决条件
  • 基准年和预测年的时间表

第二章研究方法论

  • 调查数据
  • 先决条件

第三章执行摘要

  • 调查亮点

第四章市场动态

  • 市场驱动力
  • 市场製约因素
  • 波特五力分析
  • 行业价值链分析

5.血脂异常治疗市场（按药物类型）

  • 介绍
  • 洛伐他汀
  • 阿托伐他汀
  • 瑞舒伐他汀
  • 其他

第六章血脂异常治疗市场：按分销渠道分类

  • 介绍
  • 在线的
  • 离线

7.按地区划分的血脂异常治疗市场

  • 介绍
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他
  • 中东/非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 以色列
    • 其他
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印度尼西亚
    • 泰国
    • 其他

第八章竞争格局与分析

  • 主要公司及战略分析
  • 初创企业和市场盈利能力
  • 合併、收购、协议与合作
  • 供应商竞争力矩阵

第九章公司简介

  • Pfizer
  • Novartis AG
  • Merck & Co., Inc
  • Emcure Pharmaceuticals Ltd.
  • Mylan Pharmaceuticals, Inc.
  • Sun Pharma
简介目录
Product Code: KSI061611963

The lipid disorder treatment market was valued at US$26.269 billion in 2021.

Lipids, or lipoproteins, are the fats found circulating in the bloodstream. Lipid disorders are a broad spectrum of metabolic conditions affecting blood lipid levels. They are generally characterized by elevated levels of cholesterol, triglycerides, and/or lipoproteins in the blood in association with an increased risk of (or current) cardiovascular disease. There are several easy ways to lower LDLs, including avoiding foods high in saturated fat, dietary cholesterol, and excess calories; exercising; maintaining a healthy weight; and stopping smoking. Statins are the most commonly prescribed treatments for lipid treatment.

Consumers' increasing adoption of unhealthy habits has increased various lifestyle diseases around the globe. The growing prevalence of high cholesterol levels and the increasing developments in treating lipid metabolism disorders will further augment the market growth. World Health Organization states that a third of ischemic heart disease is attributable to high cholesterol levels. Moreover, smoking and drinking have also contributed to the rising prevalence of lipid disorders, further fueling market growth.

This research study examines the lipid disorder treatment market based on various segments: drug type, distribution channel, and geography. First, a brief market overview details key driving factors and challenges. Next, Porter's five forces model comprehensively analyzes the lipid disorder treatment industry. This is followed by industry value chain analysis which determines the companies which are part of the different processes and contributing to various sectors.

The study also presents in-depth information concerning the development, trends, and industry policies and regulations affecting the lipid disorder treatment market. Moreover, the research study analyzes the overall regulatory framework of the lipid disorder treatment sector, offering stakeholders a better understanding of the key factors influencing the overall market environment.

Lipid disorder treatment market - Forecasts from 2023 to 2028 is a comprehensive and latest report. It provides vital market information to executives and interested stakeholders to enable them to get vital market information. The report also analyzes the competitive landscape, details the strategies of key market players, and plots them on our vendor matrix in four quadrants: leader, follower, challenger, and niche.

The scope and coverage of the lipid disorder treatment market report is as below:

  • Lipid disorder treatment market data tables and charts
  • Market outlook with sections on drivers, restraints, Porter's, and industry value chain analysis
  • Market assessment by drug type into lovastatin, atorvastatin, rosuvastatin, and others.
  • Detailed market trends, analysis, and graphical representation by distribution channel into online and offline.
  • A 360o view of the lipid disorder treatment market across different geographies (North America, South America, Europe, Middle East and Africa, and Asia Pacific) with further breakdown for key countries within those regions.

Different segments covered under the lipid disorder treatment market report are as below:

By Drug Type

  • Lovastatin
  • Atorvastatin
  • Rosuvastatin
  • Others

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. LIPID DISORDER TREATMENT MARKET, BY DRUG TYPE

  • 5.1. Introduction
  • 5.2. Lovastatin
  • 5.3. Atorvastatin
  • 5.4. Rosuvastatin
  • 5.5. Others

6. LIPID DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Online
  • 6.3. Offline

7. LIPID DISORDER TREATMENT MARKET, BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. United States
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. Israel
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Indonesia
    • 7.6.6. Thailand
    • 7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

  • 9.1. Pfizer
  • 9.2. Novartis AG
  • 9.3. Merck & Co., Inc
  • 9.4. Emcure Pharmaceuticals Ltd.
  • 9.5. Mylan Pharmaceuticals, Inc.
  • 9.6. Sun Pharma